{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=10",
    "query": {
      "intervention": "Part 1, Placebo Group",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 279,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T09:08:36.100Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03814590",
      "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2019-01-21",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 18,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814590"
    },
    {
      "nct_id": "NCT04402866",
      "title": "TD-0903 for ALI Associated With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lung Injury (ALI) Associated With COVID-19",
        "Lung Inflammation Associated With COVID-19"
      ],
      "interventions": [
        {
          "name": "TD-0903",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 235,
      "start_date": "2020-06-24",
      "completion_date": "2021-04-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Denver, Colorado • Sebring, Florida + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sebring",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402866"
    },
    {
      "nct_id": "NCT04167553",
      "title": "Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obese With Comorbidities",
        "Overweight With Comorbidities",
        "Type2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM15136",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2019-08-30",
      "completion_date": "2020-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167553"
    },
    {
      "nct_id": "NCT01783977",
      "title": "Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA-HIV-PT123 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NYVAC-HIV-PT1 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NYVAC-HIV-PT4 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA-HIV-PT123 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for NYVAC-HIV-PT1 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for NYVAC-HIV-PT4 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 143,
      "start_date": "2013-04",
      "completion_date": "2018-10-24",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01783977"
    },
    {
      "nct_id": "NCT06789913",
      "title": "A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)",
        "Lymphatic Malformations",
        "Vascular Malformations",
        "PIK3CA Mutation",
        "CLOVES Syndrome",
        "Klippel Trenaunay Syndrome",
        "Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)",
        "Vascular Anomalies"
      ],
      "interventions": [
        {
          "name": "RLY-2608",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2025-06-13",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789913"
    },
    {
      "nct_id": "NCT03140527",
      "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "PTI-801",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PTI-808",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Proteostasis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2017-04-10",
      "completion_date": "2020-02-27",
      "has_results": false,
      "last_update_posted_date": "2020-04-30",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140527"
    },
    {
      "nct_id": "NCT00412620",
      "title": "An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ABT-925",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 156,
      "start_date": "2006-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2011-04-27",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 11,
      "location_summary": "Anaheim, California • Cerritos, California • Garden Grove, California + 7 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412620"
    },
    {
      "nct_id": "NCT03110770",
      "title": "VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Zika Virus",
        "Zika Virus Infection",
        "Virus Diseases",
        "Flavivirus Infections",
        "Flaviviral Diseases",
        "Flaviviridae Infections",
        "RNA Virus Infections"
      ],
      "interventions": [
        {
          "name": "VRC-ZKADNA090-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-PBSPLA043-00-VP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "15 Years to 35 Years"
      },
      "enrollment_count": 2428,
      "start_date": "2017-03-29",
      "completion_date": "2019-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Edinburg, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110770"
    },
    {
      "nct_id": "NCT05417789",
      "title": "Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TGCT"
      ],
      "interventions": [
        {
          "name": "Emactuzumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SynOx Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2024-10-09",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Georgetown",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417789"
    },
    {
      "nct_id": "NCT04801420",
      "title": "Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lyme Borreliosis"
      ],
      "interventions": [
        {
          "name": "VLA15",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "5 Years to 65 Years"
      },
      "enrollment_count": 625,
      "start_date": "2021-03-08",
      "completion_date": "2025-07-02",
      "has_results": true,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-15T09:08:36.100Z",
      "location_count": 19,
      "location_summary": "Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more",
      "locations": [
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04801420"
    }
  ]
}